National Guideline Clearinghouse | Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196).

full-text ►

National Guideline Clearinghouse | Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196).



National Institute for Health and Care Excellence (NICE)

Guideline Title

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196).

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196). London (UK): National Institute for Health and Care Excellence (NICE); 2014 Nov. 50 p. (Technology appraisal guidance; no. 326).

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Aug. 45 p. (Technology appraisal guidance; no. 196).

This guideline meets NGC's 2013 (revised) inclusion criteria.